Neuroinflammation in the Central Nervous System: Exploring the Evolving Influence of Endocannabinoid System
暂无分享,去创建一个
[1] Yogeeta O. Agrawal,et al. Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease. , 2023, Current drug research reviews.
[2] M. Tremblay,et al. All roads lead to heterogeneity: The complex involvement of astrocytes and microglia in the pathogenesis of Alzheimer’s disease , 2022, Frontiers in Cellular Neuroscience.
[3] M. Tremblay,et al. Present and future of microglial pharmacology. , 2022, Trends in pharmacological sciences.
[4] Q. Pittman,et al. Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase , 2021, Neuropsychopharmacology.
[5] Jie Wu,et al. The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders , 2020, Acta Pharmacologica Sinica.
[6] J. Tytgat,et al. Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products , 2020, International journal of molecular sciences.
[7] M. Tansey,et al. Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease , 2020, Molecules.
[8] R. Mechoulam. Cannabinoids as Therapeutic Agents , 2019 .
[9] Junxia Xie,et al. Mechanisms of cannabinoid CB2 receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area , 2019, EBioMedicine.
[10] I. Ferrer,et al. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system , 2018, Biochemical pharmacology.
[11] T. Uyama,et al. Endocannabinoids and related N-acylethanolamines: biological activities and metabolism , 2018, Inflammation and Regeneration.
[12] M. Heneka,et al. Microglia: You'll Never Walk Alone! , 2018, Immunity.
[13] B. Blomberg,et al. Aging, Obesity, and Inflammatory Age-Related Diseases , 2017, Front. Immunol..
[14] Jimok Kim,et al. Distinct roles of neuronal and microglial CB2 cannabinoid receptors in the mouse hippocampus , 2017, Neuroscience.
[15] Jeremy Hall,et al. Modulating Neuroinflammation to Treat Neuropsychiatric Disorders , 2017, BioMed research international.
[16] A. Vezzani,et al. Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation. , 2017, Current pharmaceutical design.
[17] M. Hočevar,et al. Activation of CB2 receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer's disease. , 2017, European journal of pharmacology.
[18] B. Basavarajappa,et al. Endocannabinoid system in neurodegenerative disorders , 2017, Journal of neurochemistry.
[19] R. Thangavel,et al. Brain and Peripheral Atypical Inflammatory Mediators Potentiate Neuroinflammation and Neurodegeneration , 2017, Front. Cell. Neurosci..
[20] A. Lichtman,et al. Endocannabinoids: A Promising Impact for Traumatic Brain Injury , 2017, Front. Pharmacol..
[21] A. Romano,et al. Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target , 2017, Front. Neurosci..
[22] Jie Wu,et al. Brain cannabinoid receptor 2: expression, function and modulation , 2017, Acta Pharmacologica Sinica.
[23] P. Campolongo,et al. Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety , 2016, Neuropharmacology.
[24] K. Herrup,et al. Family-wide Structural Characterization and Genomic Comparisons Decode the Diversity-oriented Biosynthesis of Thalassospiramides by Marine Proteobacteria* , 2016, The Journal of Biological Chemistry.
[25] S. Skaper. Mast Cell - Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications. , 2016, CNS & neurological disorders drug targets.
[26] M. Schwartz,et al. Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. , 2016, Trends in immunology.
[27] J. Foss,et al. Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post‐ischemic pain model of complex regional pain syndrome type I in rats , 2016, The European journal of neuroscience.
[28] D. Marasco,et al. Endocannabinoid System in Neurological Disorders. , 2016, Recent patents on CNS drug discovery.
[29] A. Papanicolaou,et al. Transcriptome Analysis of the Sydney Rock Oyster, Saccostrea glomerata: Insights into Molluscan Immunity , 2016, PloS one.
[30] D. Schmitz,et al. Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus , 2016, Neuron.
[31] Sudhakar Selvaraj,et al. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness , 2016, Psychopharmacology.
[32] T. Kielian. Multifaceted roles of neuroinflammation: the need to consider both sides of the coin , 2016, Journal of neurochemistry.
[33] J. Ting,et al. The pathogenic role of the inflammasome in neurodegenerative diseases , 2016, Journal of neurochemistry.
[34] H. Baik,et al. CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease , 2016, Experimental & Molecular Medicine.
[35] S. Skaper. Commentary. Low-grade non-resolving neuroinflammation: age does matter. , 2015, CNS & neurological disorders drug targets.
[36] R. Marotta,et al. Structure of human N-acylphosphatidylethanolamine-hydrolyzing phospholipase D: regulation of fatty acid ethanolamide biosynthesis by bile acids. , 2015, Structure.
[37] J. Manzanares,et al. Role of cannabinoid CB2 receptor in the reinforcing actions of ethanol , 2015, Addiction biology.
[38] Zheng-Xiong Xi,et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice , 2014, Proceedings of the National Academy of Sciences.
[39] Shruti V. Kabadi,et al. Repeated Mild Traumatic Brain Injury Causes Chronic Neuroinflammation, Changes in Hippocampal Synaptic Plasticity, and Associated Cognitive Deficits , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[40] G. Panagis,et al. Regulation of brain reward by the endocannabinoid system: a critical review of behavioral studies in animals. , 2014, Current pharmaceutical design.
[41] P. Diaz,et al. Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy , 2014, Neuroscience.
[42] B. Stevens,et al. Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system , 2013, Current Opinion in Neurobiology.
[43] P. Goadsby,et al. Endocannabinoids in the Brainstem Modulate Dural Trigeminovascular Nociceptive Traffic via CB1 and “Triptan” Receptors: Implications in Migraine , 2013, The Journal of Neuroscience.
[44] J. Manzanares,et al. Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing, and Physical Effects of Nicotine , 2013, Neuropsychopharmacology.
[45] A. Vezzani. Fetal brain inflammation may prime hyperexcitability and behavioral dysfunction later in life , 2013, Annals of neurology.
[46] V. Brázda,et al. Bilateral Changes of Cannabinoid Receptor Type 2 Protein and mRNA in the Dorsal Root Ganglia of a Rat Neuropathic Pain Model , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[47] D. Selley,et al. Brain regional differences in CB1 receptor adaptation and regulation of transcription. , 2013, Life sciences.
[48] R. Franco,et al. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients , 2013, Neurobiology of Aging.
[49] Jijun Xu,et al. Activation of the CB2 receptor system reverses amyloid-induced memory deficiency , 2013, Neurobiology of Aging.
[50] R. Erzurumlu,et al. Development of the principal nucleus trigeminal lemniscal projections in the mouse , 2013, The Journal of comparative neurology.
[51] L. Petrocellis,et al. Why do cannabinoid receptors have more than one endogenous ligand? , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.
[52] C. Greyson,et al. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty , 2012, Journal of Lipid Research.
[53] K. Varani,et al. Cannabinoid CB2 receptor attenuates morphine‐induced inflammatory responses in activated microglial cells , 2012, British journal of pharmacology.
[54] Garth E. Terry,et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers , 2012, Molecular Psychiatry.
[55] Ben A. Barres,et al. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner , 2012, Neuron.
[56] D. Cogdell,et al. Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System , 2012, Anesthesia and analgesia.
[57] P. Chameau,et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors , 2012, Proceedings of the National Academy of Sciences.
[58] Qing-Rong Liu,et al. CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity , 2012, Journal of psychopharmacology.
[59] I. Lizasoain,et al. Cannabinoid Type 2 Receptor Activation Downregulates Stroke-Induced Classic and Alternative Brain Macrophage/Microglial Activation Concomitant to Neuroprotection , 2012, Stroke.
[60] I. Galve-Roperh,et al. CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling* , 2011, The Journal of Biological Chemistry.
[61] L. Emadi,et al. The role of central CB2 cannabinoid receptors on food intake in neonatal chicks , 2011, Journal of Comparative Physiology A.
[62] L. Devi,et al. The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic Implications , 2011, Pharmacological Reviews.
[63] Takeya Kasukawa,et al. Quantitative Expression Profile of Distinct Functional Regions in the Adult Mouse Brain , 2011, PloS one.
[64] Z. Xi,et al. Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.
[65] B. Dittel,et al. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease , 2011, Immunologic research.
[66] J. Manzanares,et al. Deletion of CB2 Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice , 2011, Neuropsychopharmacology.
[67] A. Majewska,et al. A role for microglia in synaptic plasticity? , 2011, Communicative & integrative biology.
[68] A. Świergiel,et al. Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors , 2011, Neuroscience Letters.
[69] J. Manzanares,et al. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice , 2011, Journal of psychopharmacology.
[70] Ania K. Majewska,et al. Microglial Interactions with Synapses Are Modulated by Visual Experience , 2010, PLoS biology.
[71] Miguel Martín,et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age , 2010, Diabetologia.
[72] J. Manzanares,et al. Depression‐resistant endophenotype in mice overexpressing cannabinoid CB2 receptors , 2010, British journal of pharmacology.
[73] N. Stella. Cannabinoid and cannabinoid‐like receptors in microglia, astrocytes, and astrocytomas , 2010, Glia.
[74] K. Mackie,et al. CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.
[75] J. Hallak,et al. [Therapeutical use of the cannabinoids in psychiatry]. , 2010, Revista brasileira de psiquiatria.
[76] V. D. M. A. L. D. Petrocellis. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010 .
[77] P. Reggio. Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. , 2010, Current medicinal chemistry.
[78] B. Vergès,et al. CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice , 2010, Diabetes.
[79] Rodney W. Johnson,et al. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. , 2009, Rejuvenation research.
[80] Claudio N. Cavasotto,et al. 2,3‐Dihydro‐1‐Benzofuran Derivatives as a Series of Potent Selective Cannabinoid Receptor 2 Agonists: Design, Synthesis, and Binding Mode Prediction through Ligand‐Steered Modeling , 2009, ChemMedChem.
[81] K. Psarra,et al. Anandamide Increases the Differentiation of Rat Adipocytes and Causes PPARγ and CB1 Receptor Upregulation , 2009, Obesity.
[82] G. Uhl,et al. CNS Effects of CB2 Cannabinoid Receptors , 2009 .
[83] J. Martínez-Orgado,et al. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages , 2009, Brain Research.
[84] G. Uhl,et al. Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression , 2008, Annals of the New York Academy of Sciences.
[85] E. Romero-Sandoval,et al. Neuroimmune interactions and pain: focus on glial-modulating targets. , 2008, Current opinion in investigational drugs.
[86] Xiaolu Yang,et al. TIPE2, a Negative Regulator of Innate and Adaptive Immunity that Maintains Immune Homeostasis , 2008, Cell.
[87] K. Mackie,et al. Cannabinoid Receptors: Where They are and What They do , 2008, Journal of neuroendocrinology.
[88] J. Deleo,et al. Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury , 2008, Anesthesiology.
[89] A. Mallat,et al. CB2 receptors as new therapeutic targets for liver diseases , 2008, British journal of pharmacology.
[90] K. Wright,et al. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation , 2008, British journal of pharmacology.
[91] N. E. Buckley. The peripheral cannabinoid receptor knockout mice: an update , 2008, British journal of pharmacology.
[92] A. Hohmann,et al. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain , 2008, British journal of pharmacology.
[93] C. Guaza,et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies , 2008, British journal of pharmacology.
[94] N. Stella,et al. CB2 receptor‐mediated migration of immune cells: it can go either way , 2008, British journal of pharmacology.
[95] J. Eisenach,et al. Spinal Cannabinoid Receptor Type 2 Activation Reduces Hypersensitivity and Spinal Cord Glial Activation after Paw Incision , 2007, Anesthesiology.
[96] J. Villares. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain , 2007, Neuroscience.
[97] V. Marzo,et al. Endocannabinoids and the control of energy balance , 2007, Trends in Endocrinology & Metabolism.
[98] M. Glass,et al. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain , 2007, Neuroscience Letters.
[99] L. Petrocellis,et al. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain , 2006, Neuroscience.
[100] R. Prediger,et al. The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats , 2006, Psychopharmacology.
[101] A. Zuardi. History of cannabis as a medicine: a review. , 2006, Revista brasileira de psiquiatria.
[102] Paul F. Smith,et al. Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study , 2006, Neuroscience Letters.
[103] R. Bertorelli,et al. CB2 receptor‐mediated antihyperalgesia: possible direct involvement of neural mechanisms , 2006, The European journal of neuroscience.
[104] G. Uhl,et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain , 2006, Brain Research.
[105] B. Frenkel,et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[106] R. Nitsch,et al. The Endocannabinoid Anandamide Protects Neurons during CNS Inflammation by Induction of MKP-1 in Microglial Cells , 2006, Neuron.
[107] P. McIntyre,et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons , 2005, Neuroscience.
[108] E. Ponomarev,et al. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.
[109] K. Mackie,et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.
[110] K. Mackie,et al. A Glial Endogenous Cannabinoid System Is Upregulated in the Brains of Macaques with Simian Immunodeficiency Virus-Induced Encephalitis , 2005, The Journal of Neuroscience.
[111] M. L. de Ceballos,et al. Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation , 2005, The Journal of Neuroscience.
[112] B. P. Kota,et al. An overview on biological mechanisms of PPARs. , 2005, Pharmacological research.
[113] A. Derbenev,et al. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve , 2004, The Journal of physiology.
[114] D. Thompson,et al. Expression of Cannabinoid CB1 Receptors by Vagal Afferent Neurons Is Inhibited by Cholecystokinin , 2004, The Journal of Neuroscience.
[115] S. Ikeda,et al. Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. , 2004, Molecular pharmacology.
[116] Alberto Rábano,et al. Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.
[117] T. Groblewski,et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models , 2003, The European journal of neuroscience.
[118] S. Michalek,et al. Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A , 2003, Infection and Immunity.
[119] M. Herkenham,et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.
[120] K. Waku,et al. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[121] L. Acsády,et al. Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission , 2001, The Journal of Neuroscience.
[122] Anatol C. Kreitzer,et al. Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids , 2001, The Journal of Neuroscience.
[123] George Kunos,et al. Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus , 2001, Neuron.
[124] M. Kano,et al. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals , 2001, Neuroscience Research.
[125] B. Roques,et al. Δ9‐tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect , 2001, The European journal of neuroscience.
[126] K. Hsu,et al. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons , 2001, The Journal of physiology.
[127] Sharon Anavi-Goffer,et al. Agonist-Induced Internalization and Trafficking of Cannabinoid CB1 Receptors in Hippocampal Neurons , 2001, The Journal of Neuroscience.
[128] R. Pertwee. Cannabinoid receptors and pain , 2001, Progress in Neurobiology.
[129] K. Connolly,et al. Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids , 2001, Neuroscience Letters.
[130] Anatol C. Kreitzer,et al. Retrograde Inhibition of Presynaptic Calcium Influx by Endogenous Cannabinoids at Excitatory Synapses onto Purkinje Cells , 2001, Neuron.
[131] O. Manzoni,et al. Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. , 2001, European journal of pharmacology.
[132] David Robbe,et al. Localization and Mechanisms of Action of Cannabinoid Receptors at the Glutamatergic Synapses of the Mouse Nucleus Accumbens , 2001, The Journal of Neuroscience.
[133] T. Wenger,et al. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆ , 2000, Peptides.
[134] T. Freund,et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus , 2000, Neuroscience.
[135] I. Galve-Roperh,et al. The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase , 2000 .
[136] I. Módy,et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations , 2000, The European journal of neuroscience.
[137] M. Elphick,et al. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C‐terminal tail of CB1 , 2000, The Journal of comparative neurology.
[138] P. Soubrié,et al. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. , 2000, Journal of neurophysiology.
[139] K. Mackie,et al. Functional expression of cell surface cannabinoid CB1 receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons , 2000, Neuroscience.
[140] T. Bonner,et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.
[141] A. Hoffman,et al. Mechanisms of Cannabinoid Inhibition of GABAASynaptic Transmission in the Hippocampus , 2000, The Journal of Neuroscience.
[142] D. Linden,et al. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. , 2000, Journal of neurophysiology.
[143] E. E. Bagley,et al. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. , 2000, Molecular pharmacology.
[144] Michael L. Eads,et al. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Δ9-THC and anandamide 1 Published on the World Wide Web on 18 January 2000. 1 , 2000, Brain Research.
[145] P. Schweitzer. Cannabinoids Decrease the K+ M-Current in Hippocampal CA1 Neurons , 2000, The Journal of Neuroscience.
[146] G. Marsicano,et al. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain , 1999, The European journal of neuroscience.
[147] R. Hampson,et al. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. , 1999, The Journal of pharmacology and experimental therapeutics.
[148] J. G. Netzeband,et al. Cannabinoids Enhance NMDA-Elicited Ca2+ Signals in Cerebellar Granule Neurons in Culture , 1999, The Journal of Neuroscience.
[149] R. Mechoulam. Recent Advantages in Cannabinoid Research , 1999, Complementary Medicine Research.
[150] J. Sullivan,et al. Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons , 1999, The Journal of Neuroscience.
[151] K. Mackie,et al. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation , 1999, Neuroscience.
[152] K. Mackie,et al. Internalization and Recycling of the CB1 Cannabinoid Receptor , 1999, Journal of neurochemistry.
[153] S. McAllister,et al. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. , 1999, European journal of pharmacology.
[154] A. Ameri. The effects of cannabinoids on the brain , 1999, Progress in Neurobiology.
[155] G. Cabral,et al. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. , 1999, The Journal of pharmacology and experimental therapeutics.
[156] I. McGregor,et al. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro , 1999, British journal of pharmacology.
[157] M. Herkenham,et al. Cannabinoid receptors undergo axonal flow in sensory nerves , 1999, Neuroscience.
[158] K. Mackie,et al. Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization , 1999, The Journal of Neuroscience.
[159] K. Mackie,et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.
[160] P. Casellas,et al. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. , 1998, The Journal of pharmacology and experimental therapeutics.
[161] T. Herdegen,et al. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins , 1998, Brain Research Reviews.
[162] R. Pertwee,et al. Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice , 1998, Neuropharmacology.
[163] P. Soubrié,et al. Cannabinoids decrease excitatory synaptic transmission and impair long‐term depression in rat cerebellar Purkinje cells , 1998, The Journal of physiology.
[164] K. Starke,et al. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum , 1998, Neuroscience.
[165] W. Yung,et al. Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist , 1998, Neuroreport.
[166] R. Spencer,et al. Immunohistochemical localization of the neural cannabinoid receptor in rat brain , 1998, Journal of neuroscience research.
[167] J. Zentner,et al. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[168] R. Pertwee,et al. Action of δ-9-tetrahydrocannabinol on gabaa receptor-mediated responses in a grease-gap recording preparation of the rat hippocampal slice , 1997, Neuropharmacology.
[169] Stephen P. H. Alexander,et al. Influence of Cannabinoids on Electrically Evoked Dopamine Release and Cyclic AMP Generation in the Rat Striatum , 1997, Journal of neurochemistry.
[170] M. Glass,et al. Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor , 1997, The Journal of Neuroscience.
[171] Sean P. Brown,et al. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. , 1997, Journal of neurophysiology.
[172] N. Kaminski,et al. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. , 1997, Toxicology and applied pharmacology.
[173] S. Deadwyler,et al. Role of cyclic AMP in the actions of cannabinoid receptors. , 1996, Biochemical pharmacology.
[174] P. Casellas,et al. Characterization of two cloned human CB1 cannabinoid receptor isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.
[175] J. Brotchie,et al. Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus , 1996 .
[176] M. Shen,et al. Cannabinoid Receptor Agonists Inhibit Glutamatergic Synaptic Transmission in Rat Hippocampal Cultures , 1996, The Journal of Neuroscience.
[177] C. Ashby,et al. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. , 1996, The Journal of pharmacology and experimental therapeutics.
[178] A. Buriani,et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[179] P. Casellas,et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. , 1995, The Biochemical journal.
[180] P. Soubrié,et al. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[181] S. Galiègue,et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.
[182] J. Walker,et al. Effects of a cannabinoid on spontaneous and evoked neuronal activity in the substantia nigra pars reticulata. , 1995, European journal of pharmacology.
[183] M. Kaghad,et al. An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*) , 1995, The Journal of Biological Chemistry.
[184] R. Pertwee,et al. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. , 1994, European journal of pharmacology.
[185] S. Munro,et al. Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.
[186] M. Herkenham,et al. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[187] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[188] N. Bowery,et al. GABAA and GABAB receptor site distribution in the rat central nervous system , 1987, Neuroscience.
[189] R. Razdan,et al. Structure-activity relationships of the cannabinoids. , 1986, NIDA research monograph.
[190] L E Hollister,et al. Health aspects of cannabis. , 1986, Pharmacological reviews.
[191] J. Penney,et al. Quantitative autoradiographic distribution of L-[3H]glutamate-binding sites in rat central nervous system , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[192] W. Dewey,et al. Some 9-hydroxycannabinoid-like compounds. Synthesis and evaluation of analgesic and behavioral properties. , 1979, Journal of medicinal chemistry.
[193] B. Martin,et al. 9-Nor-9-hydroxyhexahydrocannabinols. Synthesis, Some behavioral and analgesic properties, and comparison with the tetrahydrocannabinols. , 1976, Journal of medicinal chemistry.
[194] E. May,et al. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. , 1975, Journal of medicinal chemistry.
[195] R. Mechoulam,et al. Chemical Basis of Hashish Activity , 1970, Science.
[196] R. Mechoulam,et al. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish , 1964 .
[197] On the Preparations of the Indian Hemp, or Gunjah (Cannabis Indica), Their Effects on the Animal System in Health, and Their Utility in the Treatment of Tetanus and Other Convulsive Diseases , 1840, The British and foreign medical review.
[198] Salvatore Chirumbolo,et al. Immune dysfunction and neuroinflammation in autism spectrum disorder. , 2016, Acta neurobiologiae experimentalis.
[199] L. Zweifel,et al. Behavioral effects of pulp exposure in mice lacking cannabinoid receptor 2. , 2012, Journal of endodontics.
[200] V. Di Marzo,et al. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. , 2010, Current medicinal chemistry.
[201] V. Di Marzo,et al. Role of endocannabinoids and endovanilloids in Ca2+ signalling. , 2009, Cell calcium.
[202] Robert A. Smith,et al. Permissive and repulsive cues and signalling pathways of axonal outgrowth and regeneration. , 2008, International review of cell and molecular biology.
[203] G. Velasco,et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? , 2007, Trends in pharmacological sciences.
[204] G. Guy,et al. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. , 2006, Medical hypotheses.
[205] L. Sim-Selley,et al. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. , 2003, Critical reviews in neurobiology.
[206] J. Berger,et al. The mechanisms of action of PPARs. , 2002, Annual review of medicine.
[207] A. Hoffman,et al. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. , 2001, Journal of neurophysiology.
[208] D. Lovinger,et al. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. , 2001, Journal of neurophysiology.
[209] M. Thiébot,et al. Behavioral Effects of Cannabinoid Agents in Animals. , 1999, Critical reviews in neurobiology.
[210] R. Pertwee. Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.
[211] A. Howlett,et al. Pharmacology of cannabinoid receptors. , 1995, Annual review of pharmacology and toxicology.
[212] W. Dewey. Cannabinoid pharmacology. , 1986, Pharmacological reviews.
[213] K. Mackie,et al. Identification functional characterization of brainstem cannabinoid CB2 receptors. , 2022 .